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Abstract 
Background & Objective: The autosomal dominant spinocerebellar ataxias (SCAs) belong 
to a large and expanding group of neurodegenerative disorders. SCAs comprise more than 40 
subtypes characterized by progressive ataxia as a common feature. The most prevalent 
diseases among SCAs are caused by CAG repeat expansions in the coding-region of the 
causative gene resulting in polyglutamine (polyQ) tract formation in the encoded protein. 
Unfortunately, there is no approved therapy to treat cerebellar motor dysfunction in SCA 
patients. In recent years, several studies have been conducted to recognize the clinical and 
pathophysiological aspects of the polyQ SCAs more accurately. This scientific progress has 
provided new opportunities to develop promising gene therapies, including RNA interference 
and antisense oligonucleotides. 
Conclusion: The aim of the current work is to give a brief summary of the clinical features of 
SCAs and to review the cardinal points of pathomechanisms of the most common polyQ 
SCAs. In addition, we review the last few years promising gene suppression therapies of the 
most frequent polyQ SCAs in animal models, on the basis of which human trials may be 
initiated in the near future. 
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1. Introduction 
The spinocerebellar ataxias (SCAs) are progressive neurodegenerative diseases with 
autosomal dominant inheritance. The global prevalence of SCAs is estimated to be 
approximately 1-5:100,000 people, with SCA3 as the most prevalent subtype [1, 2]. 
Cerebellar ataxia is the major clinical feature of this group, accompanied by the involvement 
of other neurological systems connected to the cerebellum with varying severity of symptoms. 
Knowledge of the genetic background of the SCAs is continuously expanding due to the 
development of DNA sequencing, resulting in more than 40 subtypes of SCA [3]. The most 
common genetic variation is the CAG repeat expansion in the coding region of the gene, 
which encodes polyglutamine (polyQ) in the corresponding protein. PolyQ SCAs include 
SCA1, 2, 3, 6, 7, 17 and dentatorubro-pallidoluysian atrophy (DRPLA) (Table 1) [4]. Besides 
the polyQ group, disease-causing repeat expansions have been identified in non-coding 
regions of the gene in some SCAs (SCA8, 10, 12, 31, 36, 37) similarly to Friedreich ataxia, 
which is the most common autosomal recessive cerebellar ataxia (Table 2) [4, 5]. Moreover, 
conventional mutations (point mutations, deletions, insertions) can cause certain types of 
SCA, including SCA5, 11, 13, 14, 15/16, 19/22, 21, 23, 26-29, 34, 35, 38, 40-47 (Table 3) [4-
9], whereas in some forms of SCA, including SCA4, 18, 20, 25, 30 and 32 only the genetic 
loci, but not the responsible gene, have been identified. 
The low prevalence, genetic diversity and different pathomechanisms of SCAs are the major 
difficulties in drug development. Probably the most comprehensive clinical description of 
patients with SCAs (more than 12 000 individuals) was performed by Rossi et al. in 2014 
[10]. Accordingly, the aim of the current work is to give a brief summary of the clinical 
picture of SCAs including descriptions of the novel ones, and to overview the main 
pathological alterations and therapeutic options of the most common polyQ SCAs (SCA1, 2, 
3, 6, 7) similarly to Picher-Martel et al. and Hadjivassiliou, who reported these aspects of the 
autosomal recessive and immune-mediated ataxias, respectively [11, 12]. 
 
2. Overview of characteristic alterations with a focus on potential drug targets 
Truncal and limb ataxia are the most prevalent symptoms in SCAs, therefore they are not 
appropriate features to distinguish between the different subtypes. In turn, other neurological 
signs, ophthalmological and hearing abnormalities are present with various frequencies in the 
distinct forms of SCAs, therefore the assessment of these signs may have a special importance 
during clinical examination. 
Autosomal dominant cerebellar ataxias form a large and heterogeneous group of 
neurodegenerative disorders. The different genetic backgrounds have resulted in diverse 
pathomechanisms, while the low prevalence and the diagnostic difficulties of SCAs are 
obstacles in recruiting sufficient numbers of patients for a well-designed therapeutic study. 
Due to these difficulties, there is no approved therapy to treat cerebellar motor dysfunction in 
SCA patients [3]. 
2.1. PolyQ SCAs 
The polyQ SCAs are the most frequent and the earliest-discovered SCAs, typically 
characterized by a progressive disease course. A correlation exists between the number of 
CAG repeats and severity of the disorder: the larger the CAG repeat number, the more severe 
the clinical phenotype and the earlier the age of onset. Anticipation has been observed in this 
group of neurodegenerative disorders due to the instability of the expanded repeat sequence 
during meiosis. The pathomechanism of these subtypes is the most extensively explored 
because of the identical genetic alteration (CAG repeat expansion in the coding region) and 
their frequent occurrence among SCAs. In polyQ SCAs, similarly to other polyglutamine 
disorders, the expansion of glutamine causes altered protein conformation and aggregation, 
resulting in a reduction in the physiological function of the protein and consequential toxic 
effects, which eventually lead to increased neuronal vulnerability and cell death. Gene 
suppression studies may yield options for the treatment of polyglutamine-repeat disorders. 
Most of these studies were performed in Huntington’s disease mouse models and utilized 
RNA interference (RNAi) and antisense oligonucleotides (ASO) [13].  
SCA1 
SCA1 is the first described subtype, characterized by a mean age of onset in the fourth 
decade, however it can range from childhood to late adulthood. In addition to truncal and gait 
ataxia, dysarthria and other cerebellar signs, ophthalmoparesis, pyramidal signs, dysphagia 
and bulbar signs are the most prevalent neurological abnormalities. Mild cognitive 
impairment, lower motoneuron involvement, deep sensory deficits and autonomic failure can 
be observed in some patients. SCA1 has the fastest progression of all SCAs with an annual 
increase of 2.11 points on the Scale for the Assessment and Rating of Ataxia (SARA) [14]. 
The characteristic brain MRI shows severe cerebellar and brainstem atrophy, whereas the 
neuropathological findings include severe degeneration in the primary motor cortex, basal 
forebrain, thalamus, red nucleus, motor cranial nerve nuclei (nerves III, IV, and VII-XII), 
vestibular nuclei, inferior olive, Purkinje cell layer and all deep cerebellar nuclei [15]. 
The disease-causing gene is ATXN1, located on chromosome 6, and encodes the protein 
ataxin-1. In the healthy population the CAG repeat number is less than 35, with repeats longer 
than 20 CAG triplets containing 1-3 CAT repeat interruptions, which code histidine. If the 
CAG repeat number is between 36 and 44, the pathogenicity depends on the presence of CAT 
interruptions. The presence of CAT impaction results in the absence of disease, while the 
absence of CAT interruption forms a mutable normal (36-38 CAG repeats) or full-penetrance 
allele (39-44 CAG repeats) [16, 17]. 
In the case of 30 CAG repeats, ataxin-1 is an 816 amino acid-containing protein with several 
domains and functionally important motifs (Fig. 1). Ataxin-1 protein interacts with several 
nuclear components, including RNAs, transcriptional regulators and many other proteins 
detailed below. A nuclear localization signal (NLS) motif is located near the C-terminus of 
the protein, which directs the protein to the nucleus [18]. If the CAG repeat number is in the 
normal range, ataxin-1 can enter the nucleus and it is able to exit it as well. On the other hand, 
in the case of pathological CAG repeat numbers, ataxin-1 cannot escape from the nucleus, 
which is the primary site of pathogenesis. Klement et al. described that a point mutation in the 
NLS motif (K772T) prevents ataxin-1 (82Q) from entering the Purkinje cell nucleus and this 
transgenic mouse model does not develop ataxia or Purkinje cell pathology. This observation 
suggests that mutant ataxin-1 must be transported to the nucleus to cause disease. 
Nevertheless, the self-association domain of the protein (between amino acids 495 and 605), 
which plays a role in the formation of nuclear aggregates, does not have such a crucial 
function in the disease pathogenesis [18, 19].  
Another important region of ataxin-1 is the AXH domain, a 130 amino acid long part of the 
protein interacting with a transcriptional corepressor SMRT (silencing mediator of retinoic 
acid and thyroid hormone receptors) and capicua (CIC), which is a transcriptional repressor 
protein [20, 21]. This interaction with CIC is very important because ataxin-1 can not bind 
DNA alone, while CIC has DNA-binding capability, thus ataxin-1 indirectly attaches to DNA 
and takes part in transcription [22]. Besides the AXH domain, the U2AF homology motif 
(UHM) is located near the C-terminus of ataxin-1. UHM is also an interaction point of the 
protein, where it connects to the RNA splicing factor RBM17 [23]. Lim and colleagues 
described that polyQ ataxin-1 prefers the formation of ataxin-1-RBM17 complex compared to 
ataxin-1-CIC complex, resulting in an imbalance between transcription and RNA splicing, 
which causes the pathogenesis of the disease. In addition to the polyglutamine tract, a 
phosphorylation of Ser776 (a phosphorylation site) can also contribute to the formation of the 
ataxin-1-RBM17 complex (Fig. 1) [24]. A recent study published by Bondar et al. delineated 
that Drosophila p21-activated kinase 3 (PAK3) is a modulator of ataxin-1. Loss-of-function of 
Drosophila PAK3 or PAK1 protein can reduce ataxin-1 levels, improving the SCA1 
phenotype, therefore pharmacological inhibitors of PAK might be potential therapeutics for 
SCA1 [25]. 
Three previous RNAi studies were performed using recombinant adeno-associated viruses 
(AAV) expressing short hairpin RNA (shRNA) or micro RNAs (miRNAs) targeting the 
ATXN1 gene in transgenic or knock-in mouse models [26-28]. These researches showed 
significant knockdown of ataxin-1 levels and improvement in behavioural, molecular and 
neuropathological phenotypes. Another miRNA study executed in rhesus macaques also 
provided promising results [29]. 
The expanding knowledge of the pathomechanism of SCA1 may provide therapeutic 
opportunities in the future, including the reduction of PAK3 activity, increasing CIC levels, 
dephosphorylation of pSer776 and modification of NLS (K772T). In addition, advances in 
RNAi studies in animal models may initiate human therapeutic trials in the near future, 
similar to those for Huntington’s disease. 
SCA2 
SCA2 is globally the second most frequent SCA, with a large founder population in Cuba 
[30]. The age of onset varies from early childhood to late adulthood with a mean onset in the 
early-30s. Anticipation may be considerably pronounced in SCA2, so much so that extreme 
CAG repeat length (>200) may occur, resulting in disease onset at infancy [31]. The most 
prevalent extracerebellar features are slow saccades, ophthalmoparesis, dysphagia, bulbar 
signs, parkinsonism, deep sensory alterations and urinary dysfunction. Similar to SCA1, the 
main characteristic pathological finding is olivopontocerebellar atrophy, but dopaminergic 
neurons in the substantia nigra, nigrostriatal pathways and neurons in the pallidum are more 
severely affected, whereas the deep cerebellar nuclei are relatively spared [15]. 
In SCA2 the affected gene is ATXN2, located on chromosome 12, determining the protein 
ataxin-2. In healthy individuals CAG repeat number is 31 or fewer, while alleles with 33 or 
more repeats are pathogenic. Alleles with 32 CAG repeats are called intermediate with 
unknown significance, because they do not result in obligatory disease development. 
The ATXN2 gene with 23 CAG repeats encodes a 1313 amino acid-containing protein called 
ataxin-2. Previous studies revealed that polyQ ataxin-2 microaggregates were found only in 
the cytoplasm, but not in the nucleus, of Purkinje cells, which are the primary targets in SCA2 
[32]. Moreover, ataxin-2 does not contain a nuclear localization signal in contrast to ataxin-1 
[32]. These observations support the hypothesis, that ataxin-2 functions in the cytoplasm. 
Ataxin-2 plays a role in RNA metabolism, as shown by studies indicating that ataxin-2 has 
specific motifs which enable interactions with proteins involved in RNA metabolism. These 
patterns are like-Sm motif (LSm), polyadenylate-binding protein (PABP)-interacting motif of 
ataxin-2 (PAM2) and the C-terminus of ataxin-2 which can connect to the ataxin-2 binding 
protein 1 (A2BP1) (Fig. 2) [33-35]. Satterfield et al. reported that ataxin-2 and its Drosophila 
homolog, ATX2 interconnect with polyribosomes and PABP, an important regulator of 
mRNA translation. Two regions of ATX2 are independently involved in the assembly of 
ATX2 with polyribosome, the LSm/LSm-associated domain (LSmAD) and the PAM2 motif. 
Besides this, PAM2 is also involved in the connection between ATX2 and PABP, therefore 
ATX2 can bind mRNA directly (through its LSm/LSmAD domain) and indirectly (through 
PABP), as well. These interactions suggest that ataxin-2 has a major role in translational 
regulation [36].  
Other studies also confirmed that ataxin-2 regulates RNA processing and protein translation. 
These researches are based on observations that ataxin-2 interacts with the DEAD/H-box 
RNA helicase DDX6, which is a component of stress granules (SGs) and processing bodies 
(P-bodies). Another component of SGs is PABP, a previously described interaction partner of 
ataxin-2. SGs and P-bodies are the main compartments for the regulation of mRNA stability, 
translation and degradation, while the assembly of these intracellular units depends on cellular 
ataxin-2 concentration [37]. Moreover, the ataxin-2 paralog, called ataxin-2-like, has similar 
interaction partners (RNA helicase DDX6, PABP), whereas it is a component of SGs and its 
intracellular level regulates the induction of SGs and P-bodies [38].  
The ATXN2 gene with intermediate-length CAG repeats (27-33) is associated with 
amyotrophic lateral sclerosis (ALS) as a susceptibility gene. This susceptibility was 
strengthened by animal and cellular studies demonstrating that ataxin-2 is a remarkable 
modifier of TAR DNA-binding protein 43 (TDP43), which is involved in RNA metabolism 
and has a major role in the pathogenesis of ALS [39].  
We currently have a lot of information about the interactions and function of normal 
glutamine-containing ataxin-2, however it is still unknown how the polyglutamine tract 
causes the disease. Two major hypotheses exist. The first is that the polyQ tract alters the 
interactions of ataxin-2 and its role in RNA metabolism, i.e. causing a loss of its physiological 
function. The second suggests that polyQ ataxin-2 leads to perturbations in RNA metabolism, 
causing a toxic gain-of-function (Fig. 2). 
Scoles et al. published an article about screening antisense oligonucleotides directed at the 
ATXN2 gene in mouse models in 2017. ASO7, one of these examined ASOs, showed 
encouraging results, including reduced cerebellar ATXN2 mRNA and protein levels and 
improved motor function in mice [40]. 
On the basis of the scientific results, the number of potential therapeutic targets is very 
limited, in contrast to SCA1. However, promising animal studies have been presented about 
the testing of ASO. Nevertheless, further pathophysiological studies are needed. 
SCA3 
SCA3, also known as Machado-Joseph disease (MJD) or Azorean ataxia, is the most common 
autosomal dominantly inherited ataxia worldwide. The prevalence of SCA3 is at least 50% of 
all SCAs in some countries, including Germany, Japan, Portugal, Brazil and Taiwan [41-47]. 
The clinical phenotype shows great diversity and therefore currently 5 different clinical 
subtypes can be distinguished. Type 1 is an early onset (<20 years) progressive disorder with 
pyramidal signs, ataxia and extrapyramidal features including bradykinesia, rigidity and 
dystonia. Type 2 is the most frequent form, characterized by later age of onset (20-50 years), 
cerebellar ataxia, pyramidal symptoms and progressive external ophthalmoplegia. Type 3 has 
a later onset than the previous types, generally between 40 to 75 years and the typical 
symptoms, besides ataxia, are lower motoneuron signs with muscle atrophy and motor 
neuropathy. These are the classical phenotypes of MJD, while type 4 and 5 are the most 
infrequent forms characterized by parkinsonism, ataxia and pure spastic paraplegia [48]. 
Pathologically, the primary motor cortex, the basal forebrain, the thalamus and the deep 
cerebellar nuclei are not so severely affected as compared to SCA1, while the brainstem 
nuclei and the basal ganglia are considerably damaged, as in SCA2 [15]. 
Machado-Joseph disease is caused by abnormally expanded CAG repeats in the ATXN3 gene, 
located on chromosome 14, and encoding the protein ataxin-3. Normal alleles contain 12 to 
44 CAG repeats and more than 90% of them have fewer than 31 CAG repeats. In classic 
SCA3 patients, the CAG repeat number ranges from ~60 to 87, while there is an intermediate 
range between the normal and full penetrance alleles, presenting with a non-classical form of 
MJD [48]. 
Ataxin-3 is an evolutionarily conserved 42 kDa protein which is a deubiquitinating enzyme 
(DUB), regulating ubiquitin (Ub)-dependent protein modulation (Fig. 3) [49]. The catalytic 
Josephin domain (JD) is located at the N-terminus of the ataxin-3 protein, containing two 
ubiquitin-binding sites and two nuclear export signals (NES). At the C-terminus of ataxin-3 
there are two or three ubiquitin-interacting motifs (UIMs), the polyQ tract and the nuclear-
localization signal (NLS) [48]. Presumably, JD and UIMs cooperate in positioning and 
binding the polyUb chains and JD performs the cleavage. Ataxin-3 preferentially binds 
polyUb substrates, however it can deubiquitinate monoUb chains as well. Intracellular 
localization of ataxin-3 has complex regulation and its primary intracellular position is 
uncertain. More than 100 proteins have been identified as ataxin-3 interacting partners, which 
elucidates the multiple biological functions of ataxin-3, however, knockout mouse models 
have revealed that it is not an essential protein [48, 50]. The major roles of ataxin-3 involve 
cellular protein quality control, regulation of ubiquitination status of several proteins and 
cellular response to heat stress [51, 52]. Moreover, ataxin-3 is involved in aggresome 
production, cytoskeletal organization, endoplasmic reticulum-associated degradation and 
transcriptional regulation, as well [48]. Ataxin-3 interacting partners include E3 ligases (e.g., 
CHIP and parkin), which are associated with neurodegenerative disorders [53, 54]. The 
pathomechanism, how the polyQ tract leads to the development of the disease, is still unclear. 
Animal models of polyglutamine ataxin-3 showed alterations in DUB function (enhancement 
or reduction), increased capability of nuclear aggregation, increased susceptibility to 
proteolysis resulting in the production of polyQ-containing fragments, in the reduction of 
CHIP and parkin levels in the brain, and in altered DNA binding and consequent changes in 
the regulation of RNA transcription [48]. These functional abnormalities are a mixture of 
gain-of-function and loss-of-function alterations (Fig. 3). 
Previously described studies using lentivirus expressing shRNAs targeting the ATXN3 gene in 
rat and mouse models were promising, because allele-specific shRNA prevented inclusion 
body formation, neuronal loss, and improved motor deficits, while both allele-specific and 
non-allele-specific shRNAs reduced neuropathological abnormalities [55-57]. In addition, two 
other RNAi studies were performed using AAV vectors expressing miRNAs targeting the 
ATXN3 gene in transgenic mouse and rat models. Allele-specific short-term suppression of 
ATXN3 reduced the nuclear accumulation of cerebellar ataxin-3 protein, however, the well-
tolerated lifelong gene suppression did not prevent motor abnormalities [58, 59]. Moreover, 
an ASO targeting ATXN3 in transgenic mice reduced polyQ containing ataxin-3 protein levels 
and prevented its nuclear accumulation, and furthermore, motor symptoms were also rescued 
[60]. Besides these genetic therapies, administering lactulose and melibiose in cell models 
resulted in a reduction in the aggregation of polyQ ataxin-3, which suggests the therapeutic 
potential of these trehalose analogs [61]. 
Ataxin-3 is not an essential protein, consequently reducing the levels of mutant ataxin-3 
protein seems to be a favourable therapeutic option. The previously demonstrated animal 
model studies reinforce this hypothesis, so it would be a possible treatment option for SCA3 
patients. 
SCA6 
Among the polyQ SCAs, SCA6 has the latest onset, usually beginning in the mid-40s. This is 
a pure cerebellar syndrome with a slow progression rate. Ataxia, dysarthria and nystagmus are 
the main signs, whereas tremor and mild somatosensory deficits may infrequently be 
observed. Pathological studies reveal that the principal abnormalities are located in the 
Purkinje cell layer of the cerebellum and in the primary motor cortex, while pontine, bulbar 
and deep cerebellar nuclei are mildly involved, and the diencephalon and the basal forebrain 
are relatively spared [15]. Due to the slight brainstem damage, in contrast to SCA1-3, SCA6 
does not substantially reduce lifespan [62]. 
SCA6 is caused by CAG repeat expansion in the CACNA1A gene, located on chromosome 19. 
Normal alleles contain 18 or fewer CAG repeats, while full penetrance alleles comprise 20-33 
CAG repeats, and alleles with 19 CAG repeats have questionable significance [63, 64]. 
Besides SCA6, CACNA1A gene mutations can lead to the development of other autosomal 
dominant neurological disorders, including episodic ataxia type 2, familial hemiplegic 
migraine type 1 and early infantile epileptic encephalopathy type 42.  
The CACNA1A gene encodes a bicistronic mRNA, which can be translated into two distinct 
proteins, the transmembrane pore-forming alpha-1A subunit of the voltage-dependent calcium 
channel (Cav2.1 or VGCC) and the transcription factor α1ACT, which is under the control of 
an internal ribosomal entry site (IRES) (Fig. 4) [65, 66]. The Cav2.1 calcium channel is 
highly expressed in the Purkinje cells and the granule cells of the cerebellar cortex. The 
fundamental role of these P/Q-type calcium channels is synaptic transmission. α1ACT is 
translocated to the nucleus and enhances the expression of several genes playing roles in the 
development and differentiation of Purkinje cells [66]. Both of CACNA1A-encoded proteins 
contain the polyQ tract in their C-terminus. This C-terminal polyglutamine expansion does 
not cause abnormality in the function of the calcium channel, however the polyQ-containing 
cytoplasmic carboxy terminus is cleaved, and the generated peptide is transported to the 
nucleus, producing toxic effects. In addition, the polyQ tract in α1ACT alters its gene-binding 
ability, causing a deterioration of its transcriptional function and contributing to the 
development of disease (Fig. 4). 
Miyazaki et al. reported an RNAi study using an AAV vector expressing miRNA-targeted 
IRES of the CACNA1A gene in a mouse model with early-onset SCA6. This research 
demonstrated that the reduced translation of α1ACT blocks the interaction between IRES and 
eukaryotic initiation factors (eIFs), preventing motor abnormalities and Purkinje cell 
pathology [67]. 
The polyQ containing peptides (α1ACT and the cleaved cytoplasmic carboxy terminus) play 
major roles in the pathogenesis. Reducing the levels of these proteins is an attractive 
therapeutic option. This can be achieved in many ways, including the modification of 
transcriptional, translational and posttranslational regulation or the specific binding and 
degradation of proteins.  
SCA7 
SCA7 basically begins in the third decade of life, however marked anticipation is known, 
which can be so pronounced that a child may be symptomatic years before a parent or 
grandparent developed any symptoms of the disease [68]. The most characteristic clinical 
alterations are retinal degeneration and visual impairment, which eventually lead to blindness. 
Ophthalmoparesis, pyramidal signs, dysphagia, bulbar symptoms and urinary dysfunction are 
also present, in addition to the progressive cerebellar ataxia. Pathological studies presented 
mild degeneration of the supratentorial structures and the deep cerebellar nuclei, whereas 
brainstem nuclei and Purkinje cells were severely affected [15]. The progressive retinal 
degeneration is explained by cone-rod dystrophy, which is a unique pathological finding in 
SCA7 among SCAs [69]. 
The genetic background of SCA7 is the CAG repeat expansion in the ATXN7 gene located on 
chromosome 3. Normal alleles maximally contain 19 CAG repeats, while the most prevalent 
repeat size is 10 [70]. Full-penetrance pathogenic alleles consist of greater than 36 CAG 
repeats [71]. Alleles between 28 and 36 repeats are called intermediate alleles with mutable 
normal (28 to 33) and reduced-penetrance features (34 to 36), whereas there is no available 
data regarding the significance of 20 to 27 repeats [72].  
The protein ataxin-7, encoded by the ATXN7 gene, is a 95 kDa molecule containing 892 
amino acids (in the case of 10 CAG repeats) (Fig. 5). Ataxin-7 is a component of nuclearly 
localized multi-subunit complexes (TFTC and STAGA) having histone acetyltransferase and 
deubiquitinase activity [73]. The intracellular distribution of ataxin-7 varies between the 
nucleus and the cytoplasm, in the latter connecting with the microtubules and stabilizing them 
[74]. Lan et al. reported that in vitro polyQ tract containing ataxin-7 does not change DUB 
activity of the protein complex. However, in vivo mouse models revealed that polyQ ataxin-7 
prefers the formation of insoluble aggregates that separate the DUB module of the protein 
complex, resulting in increased levels of ubiquitinated histone 2 B (H2B) [75]. These 
alterations in enzymatic activity can cause abnormalities in gene expression, leading to the 
development of disease (Fig. 5). 
Recent RNAi studies used AAV vector-delivered non-allele specific miRNAs targeting 
ATXN7 in a transgenic mouse model. The therapeutic construct was injected into the retina or 
the deep cerebellar nuclei of the mice. Both treatments were beneficial, in the first case, 
normal retinal function was preserved and there was no adverse effect, whereas cerebellar 
delivery resulted in improvement of motor deficits and amelioration of Purkinje cell 
abnormalities [76, 77]. 
Further examinations are needed for extensive understanding of the disease pathomechanism 
and to discover which molecules can regulate the function of ataxin-7. Besides these potential 
targets, promising RNAi animal model studies may provide another hopeful treatment option 
to ameliorate the symptoms of SCA7 patients. 
SCA17 
SCA17 is also called Huntington disease-like 4 (HDL4) according to the clinical phenotype 
resembling Huntington’s disease (HD). The major extracerebellar symptoms are chorea, 
dystonia, parkinsonism, seizures, pyramidal signs, dysphagia, deep sensory deficits, 
autonomic failure and cognitive impairment. The mean age of onset is the mid-30s. 
Pathological examinations revealed neuronal loss in the substantia nigra, striatum, ventral 
thalamic nuclei, inferior olive, Purkinje cell layer and in the cingulate and parahippocampal 
gyri [15].  
DRPLA 
Dentatorubral-pallidoluysian atrophy usually begins at 28-30 years, and may be characterized 
by prominent anticipation as well [78, 79]. The typical non-cerebellar symptoms are chorea, 
myoclonus, dystonia, cognitive decline and seizures. The juvenile-onset (before the age of 20) 
is characterized by progressive myoclonus epilepsy and mental retardation, whereas the later-
onset form is associated with ataxia, chorea and dementia [80]. The name of the disease 
indicates that the dentatorubral and pallidoluysian systems are affected, and furthermore, 
diffuse white and grey matter loss was also observed [15]. 
2.2. Repeat expansion in the non-coding region 
This is a less frequent group of SCAs, containing slowly progressive disorders with only mild 
or no anticipation. In contrast to the polyQ SCAs, there is a little scientific information about 
the pathomechanism or potential therapeutic targets of these diseases, and accordingly, this 
part mainly focuses on the main clinical characteristics of these disorders. 
SCA8 
SCA8 is a slowly progressive ataxia without the phenomenon of anticipation. The disease 
most commonly starts in the fourth decade of life. Patients exhibit cerebellar symptoms 
including gait and limb ataxia, dysarthria and nystagmus, while the most frequent 
extracerebellar features are pyramidal signs, cognitive impairment, ophthalmoparesis and 
deep sensory abnormalities. Brain MRI scans revealed pronounced cerebellar atrophy without 
brainstem or cerebral involvement. Pathological evaluation demonstrated the loss of Purkinje 
cells and cerebellar granular cells with degeneration of inferior olive and milder involvement 
of neurons of the substantia nigra [15, 81]. 
SCA10 
SCA10 is a rare disorder caused by pentanucleotide (ATTCT) repeat expansion and 
exclusively found in Latin American populations [82]. The first symptoms of SCA10 
typically appear at the age of 32-34 years, however anticipation was observed in a number of 
families [83, 84]. The main feature, along with cerebellar ataxia, is rare epilepsy, which is a 
special sign amongst SCAs. Brain MRI examination showed pancerebellar atrophy without 
extracerebellar involvement, while pathological data are currently unavailable [15]. 
SCA12 
SCA12 is characterized by the onset of action tremor of the hand mainly at the age of 37-40 
years. In the next years, SCA12 patients develop slowly progressive ataxia and cerebellar 
oculomotor abnormalities, while a subset of patients has parkinsonism, pyramidal signs and 
dementia. Most of the SCA12 patients were published from the Indian population and an 
American family of German origin [85-87]. Brain MRI demonstrates atrophy of both the 
cerebral cortex and the cerebellum, mainly in the vermis [88]. Postmortem neuropathological 
examination from one SCA12 patient revealed enlarged ventricles, cerebral cortical atrophy 
with milder cerebellar and pontine atrophy [89]. 
SCA31 
SCA31 is the third most common SCA in the Japanese population with a general onset in the 
sixth decade. This pentanucleotide repeat expansion disease is characterized by a purely 
cerebellar syndrome with slow deterioration rates and cerebellar atrophy observed in brain 
MRI. The few available neuropathological data demonstrated marked Purkinje cell loss [15, 
90]. 
SCA36 
SCA36 is caused by a hexanucleotide (GGCCTG) repeat expansion with mean age of onset at 
the 52-53 years. This subtype of SCA is a slowly progressive cerebellar syndrome with 
hearing loss and lower motoneuron signs, of which the latter two are relatively specific 
symptoms in this group. Brain MRI scans revealed mild cerebellar atrophy, while 
pathological examinations showed neuronal loss of the Purkinje cell layer and the dentate 
nucleus [91]. 
SCA37 
SCA37 has a relatively pure cerebellar entity with vertical eye movement abnormalities. To 
date, only a large Spanish family was identified as having SCA37, in whom the onset of the 
disease varied between 25-64 years. Brain MRI investigations revealed initial vermis atrophy 
progressing to generalized cerebellar atrophy without extracerebellar involvement. 
Postmortem pathological examinations from two SCA37 patients demonstrated extensive loss 
of Purkinje cells, neuronal loss and gliosis in the inferior olive [92].  
 
2.3. Non-repeat expansion SCAs 
This group of SCAs is caused by conventional mutations resulting in a slowly progressive 
clinical phenotype, not interfering with the lifespan of the patient. Anticipation was not 
observed in these neurodegenerative disorders. Most of these subtypes were described in the 
new generation sequencing era. Besides the considerably novel delineation of these disorders, 
their rarity also contributes to the fact that few studies have been carried out to discover the 
deep pathomechanism of these diseases which would be the fundamental basis of therapeutic 
investigations. Accordingly, the following part mainly focuses on clinical findings. 
SCA5 
In SCA5, the age of onset varies from childhood to adulthood, with an average onset at 19-24 
years. SCA5 is characterized by cerebellar symptoms with a little brainstem or spinocerebellar 
tract involvement. Patients with juvenile-onset developed pyramidal signs and bulbar 
dysfunction causing a severe phenotype [93]. Brain MRI studies revealed cerebellar cortical 
atrophy with a disproportionately massive reduction in the volume of the anterior vermis and 
the superior hemispheres [94]. Neuropathological examinations confirmed the imaging data 
with the observation of markedly reduced cerebellar weight and severe atrophy of the anterior 
vermis and adjacent cerebellar hemispheres [94, 95]. 
SCA11 
SCA11 is a slowly progressive cerebellar ataxia, which generally begins in the fifth decade of 
life. Besides cerebellar ataxia, jerky pursuit, horizontal and vertical nystagmus are the most 
common findings, while pyramidal signs, peripheral neuropathy and dystonia only 
occasionally occur [96]. Brain MRI studies revealed cerebellar atrophy with vermal 
predominance [97]. Pathological investigations demonstrated Purkinje and granular cell loss 
in the cerebellar cortex and neuronal loss in the dentate nucleus [15].  
SCA13 
SCA13 is a rare type of SCA with two different phenotypes. Patients from a French family 
can be characterized by childhood-onset cerebellar ataxia and mental retardation with a slow 
progression, while patients from the Filipino family developed adult-onset (22-60 years) 
cerebellar ataxia and dysarthria [98, 99]. Mental retardation is an uncommon feature in 
autosomal dominant cerebellar ataxias, in contrast with the recessively-inherited forms. In 
addition, myoclonus and spasticity seem to be relatively prevalent findings in SCA13 [100-
102]. The age of onset and clinical phenotype of the disease depend on the type of mutation. 
Brain MRI revealed cerebellar atrophy with variable severity, whereas pathological 
examinations were not available. 
SCA14 
SCA14 typically begins around the age of 30 years with slowly worsening gait ataxia and 
later accompanied by dysarthria, limb ataxia, cerebellar oculomotor abnormalities and 
extrapyramidal symptoms including myoclonus and dystonia. In a few cases of SCA14, facial 
myokymia, deafness, cognitive deficit, depression and deep sensory loss were also observed. 
Brain MRI examinations evaluated cerebellar atrophy predominantly in the vermis. Detailed 
neuropathological studies are not available [15, 103]. 
SCA15/16 
SCA15/16 is a very slowly progressive type of SCAs with relatively pure cerebellar 
symptoms. The most frequent additional neurological sign in SCA15/16 is postural or kinetic 
tremor of the head or upper limb, with occasional occurrence of hyperreflexia and posterior 
column signs. The disease onset ranges from childhood to adulthood with an average of 31 
years. Brain MRI scans demonstrated vermal atrophy with relatively spared cerebellar 
hemispheres and extracerebellar structures. No neuropathological examination has been 
published on these patients [15, 104].  
SCA19/22 
SCA19/22 is a slowly progressive SCA characterized by cerebellar ataxia, dysarthria, 
cognitive impairment and frontal lobe dysfunction. In a subset of patients, myoclonus, head 
tremor, pyramidal signs, parkinsonism, neuropathy and rarely epilepsy can develop [105]. 
Brain MRI investigations revealed vermal atrophy, while postmortem neuropathological 
examination evaluated the atrophy of the frontal lobe and the cerebellar cortex, and moreover, 
moderate dopaminergic neuronal loss of substantia nigra and severe loss of Purkinje cells 
predominantly in lobules 1-8 were described as well [106]. 
SCA21 
SCA21 is an early-onset (1-30 years, mean: 14-18 years) slowly worsening cerebellar ataxia, 
frequently associated with severe cognitive deficit, delayed psychomotor development and 
parkinsonism. Most of the SCA21 patients were described in the French population, only one 
Chinese person and one Japanese family with six affected individuals were reported. Brain 
MRI scans demonstrated cerebellar atrophy mainly affecting the vermis and to a lesser extent, 
the hemispheres [107-109]. Neuropathological investigations of one patient revealed severe 
loss of Purkinje cells and mild involvement of inferior olive neurons [108]. 
SCA23 
SCA23 was first described in a large Dutch family, whereas only some patients were reported 
from other ethnicities (1 British, 1 French and 1 Moroccan) [110-112]. This is a late-onset 
(49-56 years) slowly progressive, mainly isolated cerebellar ataxia with some additional 
features including slowing of saccades, ocular dysmetria, dysarthria, pyramidal signs and 
deep sensory deficits. Brain MRI revealed cerebellar atrophy, and the neuropathological 
examination demonstrated neuronal loss in the Purkinje cell layer, dentate nuclei and inferior 
olive [113]. 
SCA26 
SCA26 was first reported in a six-generation family of Norwegian ancestry manifested by 
slowly worsening pure cerebellar ataxia without extracerebellar symptoms [114]. 
Neuropathological investigation of two patients from this population was performed and 
revealed significant Purkinje cell loss, whereas other brain regions were relatively spared 
[115]. 
SCA27 
SCA27 is an extremely slowly progressive neurodegenerative disease starting with postural 
hand tremor between the ages of 6-20 years, while ataxia developed only some decades later. 
In addition, head titubation, dyskinesia, reduced vibratory sense, cognitive impairment and 
behavioural abnormalities were also observed in some patients suffering from SCA27. Brain 
MRI examinations delineated moderate cerebellar atrophy only in the later stages of the 
disorder, whereas neuropathological studies are not available [116]. 
SCA28 
SCA28 is a very slowly deteriorating type of SCAs with variable age of onset (3-70 years, 
mean: 30.15 years). SCA28 is characterized by gait and limb ataxia, dysarthria, nystagmus, 
ptosis, ophthalmoparesis and pyramidal signs [117]. Brain MRI revealed mild to moderate 
cerebellar atrophy predominantly in the vermis. whereas postmortem pathological data are not 
available [118].  
SCA29 
SCA29 is an infantile-onset non-progressive disease characterized by hypotonia, motor delay, 
cognitive impairment and cerebellar abnormalities. Brain MRI scans demonstrated cerebellar 
atrophy mainly in the vermis and in the superior part of cerebellar hemispheres [119, 120]. 
SCA34 
SCA34 is a rare form of SCA, only two large French-Canadian and two Japanese SCA34 
families have been reported in the literature so far. In the French-Canadian pedigree, the 
affected patients presented ataxia and erythrokeratodermia variabilis, in the following order: 
the dermatological abnormalities were the initial signs, developing in infancy, while ataxia 
and mild peripheral axonal neuropathy appeared only in the fourth or fifth decade of life. In 
the Japanese population, erythrokeratodermia was absent, while pyramidal signs and hot cross 
bun sign on the brain MRI were present [121, 122]. 
SCA35 
SCA35 is a slowly progressive spinocerebellar ataxia reported in several Chinese families and 
in some Caucasian patients. Age of onset ranges from 12 to 56 years. The disease is 
characterized by gait and limb ataxia, hand tremor, dysarthria, mild mental retardation, 
myoclonus, spasticity and vermis atrophy on the MRI scans [123, 124]. Postmortem 
pathological data are not available. 
SCA38 
SCA38 was identified in a few Italian families and can be characterized by gait ataxia, 
dysarthria, horizontal and vertical nystagmus, pes cavus, hyposmia and in a third of the 
patients, hearing loss and anxiety. The most prevalent initial symptom was imbalanced gait 
occurring with a variable age of onset (26-50 years). In later stages of the disease, dysphagia, 
ophthalmoparesis, sensory loss and sometimes, pyramidal symptoms also developed with 
slow progression rates. Brain MRI revealed mild cerebellar atrophy with predominance in the 
vermis [125]. 
SCA42 
SCA42 is a slowly deteriorating disorder, recently identified in French, Japanese and Chinese 
families. The most prevalent symptom at onset was gait instability, whereas a relatively pure 
cerebellar phenotype with additional pyramidal signs, orbicular myokymia and rarely, with 
mild sensory deficits, dysphagia and urinary dysfunction may also be observed in the course 
of the disease. Brain MRI demonstrated cerebellar atrophy with vermal predominance, 
whereas postmortem pathological studies have not been performed so far [126-128]. 
SCA40, 41, 43, 44-47 
In these subtypes of SCAs, a very limited number of case reports have been published yet. 
Because of the few available clinical data, the detailed phenotypical characterization is 
lacking. 
2.4. Other SCAs (SCA4, 18, 20, 25, 30, 32) 
These infrequent SCAs were described in some families, whereas only the genetic loci were 
identified by linkage analysis studies. Nevertheless, the accurate disease-causing genes were 
not determined making the recruitment of a larger number of patients to further clinical and 
molecular studies difficult. 
3. Conclusion 
The number of subtypes of spinocerebellar ataxias has significantly increased in the last 
decades along with the development of genetics. This genetic information has allowed the 
differential diagnosis of SCAs, more difficult to perform based on clinical findings. 
Moreover, several novel disease-causing genes were identified, however, the pathological 
mechanisms are only partially discovered in the new forms of SCA. Nevertheless, the most 
common polyQ SCAs have been extensively researched in the past years, similarly to HD. 
The increasing scientific information and experience about polyQ SCAs and the availability 
of novel gene suppression therapies, including RNAi and ASO, has opened a new chapter in 
the treatment of CAG repeat expansion neurodegenerative disorders. The initiation of clinical 
trials with these new therapeutic approaches requires many patients, thereby international 
patient registries are essential. In addition, further clinical and preclinical studies are needed 
to profoundly recognize the rarer subtypes of SCAs with the possibility of therapeutic 
achievements in the future. 
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